Treatment of severe obsessive-compulsive disorder with fluvoxamine.
Ten obsessive-compulsive patients received single-blind treatment with fluvoxamine, a selective serotonin reuptake inhibitor, for several weeks following at least 2 weeks of placebo. The group showed significant improvement, as measured by several clinical scales and self-ratings; six patients were judged responders. Fluvoxamine appears effective in treating severe obsessive-compulsive disorder.
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010091:Oximes / Q000627:therapeutic use*; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales
D010091:Oximes; D016666:Fluvoxamine